{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.422","value":"1.32"},{"groupId":"OG001","spread":"0.342","value":"0.403"},{"comment":"Single participant analyzed","groupId":"OG002","spread":"NA","value":"1.80"},{"groupId":"OG003","spread":"0.817","value":"1.81"}]}],"title":"Ctrough (ng/mL) Day 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.223","value":"1.03"},{"groupId":"OG001","spread":"0.365","value":"1.01"},{"comment":"Single participant analyzed","groupId":"OG002","spread":"NA","value":"1.27"},{"groupId":"OG003","spread":"0.965","value":"1.73"}]}],"title":"Ctrough (ng(mL) Day 56"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Pharmacokinetics (PK) of octreotide after administrations of CAM2029 was determined for the dosing period Day 0 to Day 84; Ctrough (ng/mL).\n\nCtrough; Concentration levels assessed prior to next injection for CAM2029 20 mg q4w and CAM2029 10 mg q2w dosing intervals (ng/mL)","dispersionType":"Standard Deviation","groups":[{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG000","title":"CAM2029 10 mg q2w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG001","title":"CAM2029 20 mg q4w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG002","title":"CAM2029 10 mg q2w (NET)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG003","title":"CAM2029 20 mg q4w (NET)"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic population, two patients excluded from the CAM2029 20mg Acromegaly due to incorrect dose.","reportingStatus":"POSTED","timeFrame":"(Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)","title":"Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Ctrough","type":"PRIMARY","unitOfMeasure":"ng/ml"}